Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.30 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.30 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19583045 | 0.98 | SI (0.40) | SISLC6A12SLC6A11SLC6A13 | |
| SCHEMBL1461057 | 0.82 | SI (0.33) | SI | |
| SCHEMBL893299 | 0.82 | SI (0.33) | SI | |
| SCHEMBL4964290 | 0.78 | GABRR1 (0.30) | — | |
| SCHEMBL14534987 | 0.76 | GABRR1 (0.33) | SI | |
| SCHEMBL25445707 | 0.74 | — | — | |
| SCHEMBL1401472 | 0.74 | SLC6A12 (0.59) | SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL9650404 | 0.73 | GBA1 (0.33) | SI | |
| SCHEMBL9650398 | 0.73 | GBA1 (0.33) | SI | |
| SCHEMBL25795374 | 0.73 | CYP2C9 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9962375-B2 | Methyl-piperidine compounds useful for inhibiting microsomal prostaglandin E2 synthase-1 | ELI LILLY AND COMPANY (US) | 2018-05-08 | — | — | US | disclosed |
| US-9962375-B2 | Methyl-piperidine compounds useful for inhibiting microsomal prostaglandin E2 synthase-1 | ELI LILLY AND COMPANY (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170326128-A1 | Novel Methyl-Piperidine Compounds Useful for Inhibiting Microsomal Prostaglandin E2 Synthase-1 | ELI LILLY AND COMPANY | 2017-11-16 | — | — | US | disclosed |
| US-20170326128-A1 | Novel Methyl-Piperidine Compounds Useful for Inhibiting Microsomal Prostaglandin E2 Synthase-1 | ELI LILLY AND COMPANY | 2017-11-16 | — | — | US | disclosed |
| WO-2016069376-A1 | NOVEL METHYL-PIPERIDINE COMPOUNDS USEFUL FOR INHIBITING MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | ELI LILLY AND COMPANY (US) | 2016-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326128-A1 | Novel Methyl-Piperidine Compounds Useful for Inhibiting Microsomal Prostaglandin E2 Synthase-1 | PTGS1, PTGES, PTGER1 | SI 3987/4885SLC6A12 4284/4885SLC6A11 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.